90 related articles for article (PubMed ID: 2130805)
1. Natural killer (NK) activity in patients with Hodgkin's disease before, during and after multiple-agent therapy.
Frydecka I; Kotlarek-Haus S; Kuliszkiewicz-Janus M; Kuliczkowski K
Arch Immunol Ther Exp (Warsz); 1990; 38(5-6):407-14. PubMed ID: 2130805
[TBL] [Abstract][Full Text] [Related]
2. Normal natural killer cell activity in Hodgkin's disease patients in remission.
Douer D; Shaked N; Ramot B
Clin Exp Immunol; 1987 Sep; 69(3):660-7. PubMed ID: 3665188
[TBL] [Abstract][Full Text] [Related]
3. Surface markers and cytotoxic activity of blood natural killer cells studied at the single cell level in Hodgkin's disease.
Jezewska E; Björkholm M; Giscombe R; Holm G; Tullgren O
Clin Exp Immunol; 1985 Jul; 61(1):96-102. PubMed ID: 4042422
[TBL] [Abstract][Full Text] [Related]
4. Natural killer activity in spleens and lymph nodes from patients with Hodgkin's disease.
Ruco LP; Procopio A; Uccini S; Marcorelli E; Baroni CD
Cancer Res; 1982 May; 42(5):2063-8. PubMed ID: 6175405
[TBL] [Abstract][Full Text] [Related]
5. Interferon enhanced natural killer function in Hodgkin's disease.
Levy S; Reins F; Aleksijevic A; Giron C; Oberling F; Mayer S; Lang JM
Nouv Rev Fr Hematol (1978); 1986; 28(5):323-5. PubMed ID: 3808943
[TBL] [Abstract][Full Text] [Related]
6. Reduced natural killer cell activity in non-hodgkin's lymphoma.
Neri A; Brugiatelli M; Ozger Topuz U; Astaldi G
Boll Ist Sieroter Milan; 1981 Nov; 60(5):394-407. PubMed ID: 7041921
[TBL] [Abstract][Full Text] [Related]
7. [Activity of natural cytotoxic cells in non-Hodgkin's lymphoma].
Frydecka I; Kotlarek-Haus S; Kuliczkowski K; Kuliszkiewicz-Janus M
Pol Tyg Lek; 1992 Apr 20-27; 47(16-17):357-9. PubMed ID: 1437753
[TBL] [Abstract][Full Text] [Related]
8. Increased number of functionally defective large granular lymphocytes in lymphoma patients.
Muhonen T; Teerenhovi L; Saksela E
Nat Immun Cell Growth Regul; 1987; 6(2):57-64. PubMed ID: 3600676
[TBL] [Abstract][Full Text] [Related]
9. [The effect of sera of breast cancer patients on NK cell activity].
Konjević G; Spuzić I
Srp Arh Celok Lek; 1995; 123(9-10):227-31. PubMed ID: 17974436
[TBL] [Abstract][Full Text] [Related]
10. [Prognostic analysis of patients with nasal-type NK/T-cell non-Hodgkin's lymphoma--a report of 93 cases].
Pan ZH; Huang HQ; Lin XB; Xia YF; Xia ZJ; Peng YL; Cai QQ; Lin TY; Jiang WQ; Guan ZZ
Ai Zheng; 2005 Dec; 24(12):1493-7. PubMed ID: 16351799
[TBL] [Abstract][Full Text] [Related]
11. Natural killer cell activity during the course of disease in patients with Hodgkin's disease.
Frydecka I
Cancer; 1985 Dec; 56(12):2799-803. PubMed ID: 4052954
[TBL] [Abstract][Full Text] [Related]
12. Immunomodulation of early engrafted natural killer cells with interleukin-2 and interferon-alpha in autologous stem cell transplantation.
Porrata LF; Inwards DJ; Lacy MQ; Markovic SN
Bone Marrow Transplant; 2001 Oct; 28(7):673-80. PubMed ID: 11704790
[TBL] [Abstract][Full Text] [Related]
13. Natural killer cell numbers and cytotoxic activity in pediatric Hodgkin disease.
Ikincioğullari A; Doğu F; Babacan E; Oflaz G; Ertem U; Yavuz G; Unal E; Gözdaşoğlu S; Taçyildiz N; Dağdemir A; Cavdar AO
Pediatr Hematol Oncol; 2000 Mar; 17(2):133-9. PubMed ID: 10734655
[TBL] [Abstract][Full Text] [Related]
14. Natural killer and activated killer activities in chronic liver disease and hepatocellular carcinoma: evidence for a decreased lymphokine-induced activity of effector cells.
Hirofuji H; Kakumu S; Fuji A; Ohtani Y; Murase K; Tahara H
Clin Exp Immunol; 1987 May; 68(2):348-56. PubMed ID: 2820634
[TBL] [Abstract][Full Text] [Related]
15. Time-course of the recovery of cellular immune function after high-dose chemotherapy and peripheral blood progenitor cell transplantation for high-grade non-Hodgkin's lymphoma.
Scheid C; Pettengell R; Ghielmini M; Radford JA; Morgenstern GR; Stern PL; Crowther D
Bone Marrow Transplant; 1995 Jun; 15(6):901-6. PubMed ID: 7581089
[TBL] [Abstract][Full Text] [Related]
16. [Cytotoxicity of effector cells of the peripheral blood, lymph nodes and spleen in Hodgkin's disease].
Blokhina NG; Bykovskaia SN; Kharabadze MV; Kupriianova TA; Agafonov VA
Biull Eksp Biol Med; 1989 Nov; 108(11):600-3. PubMed ID: 2633827
[TBL] [Abstract][Full Text] [Related]
17. Natural killer activity and antibody-dependent cellular cytotoxicity in patients with non-Hodgkin's lymphoma.
Metha BA; Advani SH; Nadkarni SJ
Neoplasma; 1988; 35(1):61-8. PubMed ID: 3352838
[TBL] [Abstract][Full Text] [Related]
18. [Natural killer activity in patients with malignant melanoma].
Masserini C; Villa ML; Rovini D; Clerici E
Boll Ist Sieroter Milan; 1981; 60(4):307-15. PubMed ID: 7326104
[TBL] [Abstract][Full Text] [Related]
19. Cytotoxic activity of lymphocytes from patients with Hodgkin's disease.
Holm G; Björkholm M; Mellstedt H; Johansson B
Clin Exp Immunol; 1975 Sep; 21(3):376-83. PubMed ID: 1081933
[TBL] [Abstract][Full Text] [Related]
20. Natural killer cell activity in patients with adenocarcinoma in the upper gastrointestinal tract.
Aparicio-Pagés MN; Verspaget HW; Peña AS; Lamers CB
J Clin Lab Immunol; 1991 May; 35(1):27-32. PubMed ID: 1668287
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
